Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

347.50DKK
16 Aug 2019
Change (% chg)

kr.4.60 (+1.34%)
Prev Close
kr.342.90
Open
kr.339.60
Day's High
kr.347.70
Day's Low
kr.338.40
Volume
3,385,624
Avg. Vol
2,459,338
52-wk High
kr.349.70
52-wk Low
kr.265.15

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 20.21 29.89 32.67
EPS (TTM): 15.40 -- --
ROI: 76.65 14.89 14.48
ROE: 84.84 16.01 15.78

Novo Nordisk contests Danish lawsuit claiming $1.75 billion

COPENHAGEN Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement.

Aug 16 2019

Novo Nordisk sued in Denmark for alleged market manipulation - media

COPENHAGEN, Aug 16 Danish insulin-maker Novo Nordisk has been sued by investors demanding 11.8 billion Danish crowns ($1.8 billion) in compensation for the company's alleged market manipulation, Danish daily Borsen reported on Friday.

Aug 16 2019

UPDATE 2-Italy leads European shares lower on political uncertainty

* Italian banks tumble after Salvini calls time on government

Aug 09 2019

Novo Nordisk's new diabetes, obesity drugs lift sales outlook

COPENHAGEN Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline.

Aug 09 2019

UPDATE 2-Novo Nordisk's new diabetes, obesity drugs lift sales outlook

* Upbeat about sales of its newest diabetes drug (Adds CEO quotes)

Aug 09 2019

Diabetes drug maker Novo Nordisk buys pill factory in North Carolina

COPENHAGEN Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

Aug 07 2019

UPDATE 1-Diabetes drug maker Novo Nordisk buys pill factory in North Carolina

COPENHAGEN, Aug 6 Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

Aug 07 2019

BRIEF-Novo Nordisk: PIONEER 6 Trial Achieved Its Primary Endpoint

* SAID ON TUESDAY THE PIONEER 6 TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE

Jun 12 2019

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

Jun 11 2019

CORRECTED-Oral Novo Nordisk diabetes drug poses no more heart risk than placebo -study

June 11 An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

Jun 11 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates